On June 2, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") and United Imaging Healthcare North America, Inc. ("United Imaging") reported the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The companies will evaluate the combination of United Imaging’s scanner platforms, software, connectivity and AI capabilities with Telix’s molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization by:
Enhancing integration between imaging systems and radiopharmaceutical workflows.
Enabling consistent, protocol-driven imaging performance across systems and sites.
Supporting treatment planning, monitoring, and longitudinal patient management.
Advancing data-driven and AI-enabled clinical decision support tools.
Jeffrey M. Bundy, Ph.D., President & Chief Commercial Officer, United Imaging Healthcare North America, said: "Theranostics represents a fundamental shift toward more integrated and personalized cancer care. Through this collaboration with Telix, we aim to explore how deeply integrated imaging, AI, and radiopharmaceutical workflows can be combined to support routine clinical use at scale."
Kevin Richardson, CEO, Telix Precision Medicine, added, "Realizing the full potential of theranostics requires close alignment between state-of-the-art scanners, integrated software solutions, and radiopharmaceutical innovation. By working with United Imaging, we are exploring new ways to deliver more seamless, data-driven workflow solutions that can support clinicians in their decision making, leading to better patient outcomes."
The collaboration will initially focus on TLX101-Px (Pixclara1, Floretyrosine F 18) in the U.S, with potential expansion into additional markets, and other Telix products and product candidates, subject to mutual agreement. Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.
About TLX101-Px
TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. In April 2026, the U.S. Food and Drug Administration (FDA) accepted Telix’s New Drug Application (NDA) for review, and assigned a PDUFA2 goal date of September 11, 2026.
TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (131I-iodofalan), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma3. TLX101-Px has not received a marketing authorization in any jurisdiction.
(Press release, Telix Pharmaceuticals, JUN 2, 2026, View Source [SID1234666403])